Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Monte Rosa Therapeutics Inc (NQ: GLUE )

4.900 +0.400 (+8.89%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 105,187
Open 4.670
Bid (Size) 4.500 (1)
Ask (Size) 4.950 (2)
Prev. Close 4.500
Today's Range 4.440 - 4.940
52wk Range 2.440 - 8.840
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
GLUE Stock Earnings: Monte Rosa Therapeutics Beats EPS, Beats Revenue for Q2 2024
GLUE stock results show that Monte Rosa Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-14.19%
-14.19%
1 Month
+0.62%
+0.62%
3 Month
-6.13%
-6.13%
6 Month
-11.39%
-11.39%
1 Year
-24.27%
-24.27%

More News

Read More
Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Monte Rosa Therapeutics: Q4 Earnings Insights
Via Benzinga
Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Monte Rosa Therapeutics Announces Leadership Team Promotions
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Monte Rosa Therapeutics to Present at the Jefferies Global Healthcare Conference
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel Disease
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
GLUE Stock Earnings: Monte Rosa Therapeutics Beats EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific Officer
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Why Westport Fuel Systems Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
GLUE Stock Earnings: Monte Rosa Therapeutics Misses EPS for Q4 2023
Via InvestorPlace
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1β Pathway Inhibitor
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Monte Rosa Therapeutics' AI And Machine Learning Platform Is Adding Significant Value Creation in Cancer Research: Analyst
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
3 Incredible Growth Stocks That Could Soar in 2024, According to Wall Street
Via The Motley Fool
Veradigm, Aehr Test Systems, Saratoga Investment And Other Big Stocks Moving Lower On Wednesday
Via Benzinga
Topics Stocks
Exposures US Equities
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.